tiprankstipranks
Bio-Path Holdings Shifts Focus to Metabolic Program
Company Announcements

Bio-Path Holdings Shifts Focus to Metabolic Program

Story Highlights

Pick the best stocks and maximize your portfolio:

Bio-Path Holdings ( (BPTH) ) just unveiled an announcement.

Bio-Path Holdings announced its strategic focus on the development of BP1001-A as a potential treatment for obesity in Type 2 diabetes patients, supported by scientific evidence linking Grb2 protein downregulation to improved insulin signaling and lower blood glucose levels. The company has decided to reallocate resources to its metabolic program while discontinuing the Phase 1 study of BP1002 for certain blood cancers due to enrollment challenges, indicating a shift in priorities that may impact its operational strategy and market focus.

More about Bio-Path Holdings

Bio-Path Holdings, Inc. is a biotechnology company that develops targeted nucleic acid cancer drugs using its proprietary DNAbilize® liposomal delivery and antisense technology. The company focuses on creating RNAi nanoparticle drugs, including its lead product candidate, prexigebersen (BP1001), which targets the Grb2 protein for blood cancers, and BP1001-A, a modified version for solid tumors.

YTD Price Performance: -92.28%

Average Trading Volume: 1,201,981

Technical Sentiment Consensus Rating: Strong Buy

Current Market Cap: $3.08M

For detailed information about BPTH stock, go to TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskBio-Path Holdings Faces Nasdaq Compliance and Strategic Changes
TheFlyBio-Path outlines rationale for development of BP1001-A
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App